Oncology Trial Times On the Increase
KMR Group recently assessed the duration of oncology trials and found a steady rise
KMR Group recently assessed the duration of oncology trials and found a steady rise in late stage oncology cycle times in the last 10 years. KMR Group assessed cycle time trends for more than 4,100 oncology trials using proprietary industry data across 32 companies and found that Phase II oncology trials require about one additional year, compared to trials conducted a decade ago. Phase III trials are taking almost five years, which is one and a half years longer than trials in 2003-2005. KMR defines study duration as the interval from protocol approval to database Lock.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
